Lewis  

Emerging New Agents in Diabetic Kidney Disease
(Julia Lewis, MD. ASN Renal Week 2005). There are at least five new approaches beyond ACE inibitors to diabetic nephropathy: Aldosterone blockers, ruboxistaurin, prifenidone, COX-2 inhibition, and sulodexide. What is the rationale for each of these interventions and what do the early pilot studies show?
(more...)



Williams  

Coronary Angioplasty and Stenting: Indications and Results
(Mark Williams, MD. ASN Renal Week 2005). In diabetics mortality with CAD is increased and classically they do worse with percutaneous interventions due to restenosis rathen than with bypass surgery. Is this also true for diabetic patients with CKD? To what extent has the picture changed with the use of drug-eluting stents? What are the anti-thrombotic strategies that can be used in such patients after stenting and how do these influence outcomes?
(more...)



McGill

The Role of Glycemic Control and How Best to Achieve it
(ASN Renal Week Clinical Nephrology Conference November, 2005, Philadelphia, PA)
To what extent does HbA1c predict adverse events in diabetics? In non-diabetics? How low must one go to avoid the increased CV risk? Is <7.0% low enough? What did follow-up from the DCCT/EDIC trials show? What is the benefit of multiple risk factor reduction (Steno-2 Trial)? What is the modern approach to glucose control, including use of metformin (in non-CKD), alpha-glucosidase inhibitors, incretins, secretagogues, and thiazolidinediones? What are practical points regarding use of PPAR-gamma agonists, exenatide? What are the benefits of the thiazolidinediones in terms of lipids, prevention of restenosis, and reduction of albuminuria? (more...)

Updated: August 27, 2008 (A27)
A27 Debate flares: Can obese patients be healthy?
A26 More cases of fatal pancreatitis after Byetta reported.
A26 Leptin injections keep rats with type 1 diabetes alive without insulin.
A20 New survey shows obesity rates continue to increase in the United States.
A19 Low-level arsenic exposure linked to increased type 2 diabetes risk.
A19 Obesity epidemic due to increased food intake, and not decreased activity level.
A19 FDA warns of hemorrhagic necrotizing pancreatitis with Byetta (exenatide)
A07 Bile acids play a role in glucose metabolism and insulin signaling.
A06 Broccoli compounds reduce reactive oxygen species induced in blood vessels by hyperglycemia.
A01 Consensus statement suggests that HbA1c is the best test to detect early diabetes.
J31 Two new drugs have profound effects on exercise conditioning in mice.
J29 New study highlights risk of losing bone density while following a low-calorie diet for weight loss.
J29 Testosterone changes associated with perimenopausal increase in metabolic syndrome risk.
J24 Complement activation is increases in patients with age-related macular degeneration.
J24 In acute study, fructose increases lipogenesis relative to glucose.
General Advances Emphasis
archive
Emerging New Agents in Diabetic Kidney Disease (Lewis) ASN 2005 Renal Week
Coronary Angioplasty and Stenting: Indications and Results (Williams) ASN 2005 Renal Week
Disease Management Actually Works in Dialysis Patients (Sands) RRI 2006, Part 2 (handouts)
Optimizing the Total Care of the Diabetic Patient with Kidney Disease - Lipids (Molitch) ASN Renal Week 2005
Optimizing the Total Care of the Diabetic with Kidney Disease (McGill, Kaplan, Molitch, Williams) ASN Renal Week 2005 (audiofiles)
Obesity and the Kidney (Lord, Scherer, Fliser) ASN Renal Week 2005 (audiofiles)
Novel Pathways for Prevention of Diabetes and Obesity-Related Renal and Vascular Disease (Cooper, Danesh) ASN Renal Week 2005 (audiofiles)
Newer Approaches to Diabetic Kidney Disease (Hollenberg, Lewis, Pavlakis) ASN Renal Week 2005 (audiofiles)
Diabetes and Dialysis (Oreopoulos, Friedman, Dasgupta, Kopple) ADC 2005 (audiofiles)
The Metabolic Syndrome and Kidney Disease: An Important Complication of Systemic Vascular Disease (Tuttle) ASN 2004
New Insights in the Pathogenesis of Uric Acid Nephrolithiasis (Sakhaee) ASN 2004

Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: A Scientific Statement From American Heart Association (Kumanyika SK et al) Circulation Jul 08
Screening for Type 2 Diabetes Mellitus in Adults: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med (Jun 2008)
Large artery stiffening with weight gain in humans: role of visceral fat accumulation Hypertens (Jun 2008)
Debate: Weight loss and blood pressure control (Pro) vs. Dietary therapy for obesity: an emperor with no clothes (Con) Hypertens (Jun 2008)
Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med (May 2008)
Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care Diabet Care (May 2008)
Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabet Care (Apr 2008)
Hyperglycemia and acute coronary syndrome: A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation (Mar 2008)
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: Update regarding thiazolidinediones: a consensus statement from the ADA/EASD Diabet Care (Jan 2008)
Adiponectin, cardiovascular function, and hypertension Hypertens (Jan 2008)
Rosiglitazone decreases albuminuria in type 2 diabetic patients (Miyazaki et al) Kidney Int (Dec 2007)
Long term pharmacotherapy for obesity and overweight: updated meta-analysis (Rucker et al) Brit Med J (Dec 2007)
2007 Chronic angina focused update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the ACC/AHA Task Force (Fraker Jr et al) Diabet Care (Dec 2007)
Obesity paradox in patients with hypertension and coronary artery disease (Lavie et al) Am J Med (Oct 2007)
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review (Eurich et al) Brit Med J (Sep 2007)
Impact of glucose levels on advanced glycation end products in hemodialysis (Godfrey) Hemodial Int (Jul 2007)
Intensive versus moderate blood-pressure control in normotensive patients with type 2 diabetes (Briggs J) NCPN Jun 07
Hypomagnesemia in patients with type 2 diabetes (Pham et al) CJASN (03-2007)
Hypomagnesemia in patients with type 2 diabetes CJASN 03-07
KDOQI Clinical Practice Guidelines and CPRs (2006 update) for Treatment of Diabetes and CKD AJKD (Feb 07)
(2006 Pharma )Year in Review (Michele B. Kaufman, PharmD, RPh) Dial-Transplant 12-06
ACE2: A new target for prevention of diabetic nephropathy? (Ingelfinger JR, commenting on an article by Batlle's group) JASN 11-06
Advanced glycation end products and nephrotoxicity of high-protein diets (Uribarri, Tuttle) CJASN 11-06
Angiotensin-converting enzyme-2 (ACE-2) - a new player in the genesis of glomerular injury? (Comment by Ritz on paper by Oudit et al) JASN 10-06
Management of dyslipidemias in patients with diabetes and chronic kidney disease (Molitch). CJASN 09-06
KDOQI
GUIDELINES
Diabetes and CKD, 2006 update
Diabetes Links
GENERAL
Am Diabetes Assoc
HDCN Topic Pages (KEY)
Diabetic GN
Progression
Diabetes in ESRD
Obesity, Pre-diabetes
Kidney in HTN